Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for Long-Term psoriasis relief

NCT ID NCT05364554

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new oral medication, JNJ-77242113, for long-term control of moderate-to-severe plaque psoriasis. 227 adults who completed a previous 16-week study continued treatment for up to 36 more weeks. The goal was to see how well the drug kept skin clear over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

227 people

The number who actually took part.

Started

Jun 2022

Finished

Sep 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have completed the Week 16 visit in Protocol 77242113PSO2001 * In the opinion of the investigator, may benefit from inclusion in this long term extension (LTE) study * Must agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study * Must agree to discontinue all topical therapies that could affect psoriasis or the psoriasis area severity index (PASI) or investigator's global assessment (IGA) evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention * Agree not to receive a live virus or live bacterial vaccination during the study, or within 4 weeks after the last administration of study intervention Exclusion Criteria: * Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason * Has received any biologic therapy or experimental therapy since completion of the originating study, 77242113PSO2001 * Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention * Has received the bacille Calmette-Guerin (BCG) vaccine within 12 months of the first administration of study intervention * Currently has hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or has other clinically active liver disease, or tests positive for HBsAg or anti-HCV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • Alliance Clinical Trials

    Waterloo, Ontario, N2J 1C4, Canada

  • Arlington Dermatology

    Rolling Meadows, Illinois, 60008, United States

  • CRS Clinical Research Services Berlin GmbH

    Berlin, 13627, Germany

  • Center for Clinical Studies

    Houston, Texas, 77004, United States

  • Center for Clinical Studies

    Webster, Texas, 77598, United States

  • Centre Hospitalier Le Mans

    Le Mans, 72037, France

  • Chang Gung Memorial Hospital

    Kaohsiung City, 83342, Taiwan

  • Chang-Gung Memorial Hospital, LinKou Branch

    Taoyuan, 333, Taiwan

  • Derma-Study-Center Friedrichshafen GmbH

    Friedrichshafen, 88045, Germany

  • Dermatrials Research

    Hamilton, Ontario, L8N 1Y2, Canada

  • Dermed Centrum Medyczne Sp z o o

    Lodz, 90-265, Poland

  • Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S C

    Osielsko, 86031, Poland

  • Fachklinik Bad Bentheim

    Bad Bentheim, 48455, Germany

  • Forcare Clinical Research Inc

    Tampa, Florida, 33613, United States

  • Gemeinschaftspraxis Scholz/Sebastian/Schilling

    Mahlow, 15831, Germany

  • Guys and St Thomas NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • HIA Sainte Anne

    Toulon, 83800, France

  • Hamzavi Dermatology

    Fort Gratiot, Michigan, 48059, United States

  • Hautarztpraxis

    Witten, 58453, Germany

  • Hopital Charles Nicolle

    Rouen, 76031, France

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041, Spain

  • Hosp. Univ. Germans Trias I Pujol

    Barcelona, 08916, Spain

  • Hosp. Univ. I Politecni La Fe

    Valencia, 46026, Spain

  • Hosp. de Manises

    Valencia, 46940, Spain

  • ISA - Interdisciplinary Study Association GmbH

    Berlin, 10789, Germany

  • Indiana Clinical Trial Center

    Plainfield, Indiana, 46168, United States

  • Innovaderm Research Inc.

    Montreal, Quebec, H2H2B5, Canada

  • Klinika Ambroziak Estederm Sp. z o.o

    Warsaw, 02-953, Poland

  • Konkuk University Medical Center

    Seoul, 05030, South Korea

  • Kume Clinic

    Sakai, 593 8324, Japan

  • KyungHee University Hospital

    Seoul, 102-1703, South Korea

  • MensingDerma research GmbH

    Hamburg, 22391, Germany

  • Modern Research Associates

    Dallas, Texas, 75231, United States

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

  • National Taiwan University Hospital

    Taipei, 10048, Taiwan

  • Niesmann & Othlinghaus GbR

    Bochum, 44793, Germany

  • Nomura Dermatology Clinic

    Yokohama, 221 0825, Japan

  • Nzoz Zdrowie Osteo-Medic

    Bialystok, 15-351, Poland

  • Oregon Dermatology and Research Center

    Portland, Oregon, 97210, United States

  • Pacific Skin Institute

    Sacramento, California, 95815, United States

  • Premier Clinical Research

    Spokane, Washington, 99202, United States

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Renstar Medical Research

    Ocala, Florida, 34470, United States

  • Rosenpark Research GmbH

    Darmstadt, 64283, Germany

  • Sapporo Skin Clinic

    Sapporo, 060-0063, Japan

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Shirasaki Dermatology Clinic

    Takaoka, 933-0871, Japan

  • Shizuoka General Hospital

    Shizuoka, 420-8527, Japan

  • Takagi Dermatological Clinic

    Obihiro-shi, 080-0013, Japan

  • Toyama Prefectural Central Hospital

    Toyama, 930 8550, Japan

  • Universitaetsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • Universitatsklinikum Frankfurt

    Frankfurt am Main, 60590, Germany

  • Universitatsklinikum Schleswig Holstein Kiel

    Kiel, 24105, Germany

  • University Hospital Southampton NHS Foundation Trust

    Southampton, SO16 6YD, United Kingdom

  • University of Pittsburgh Department of Dermatology

    Pittsburgh, Pennsylvania, 15213, United States

  • Vivida Dermatology

    Las Vegas, Nevada, 89119, United States

  • Windsor Dermatology, PC

    East Windsor, New Jersey, 08520, United States

  • Wro Medica

    Wroclaw, 51-685, Poland

  • XLR8 Medical Research

    Windsor, Ontario, N8T 1E6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.